[Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: Analysis of French data from the PROKALE multinational European study].

Date publication

mai 2021

Journal

Nephrologie & therapeutique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Rossignol P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33994135

Résumé

Recurrent hyperkalaemia may result in underutilisation of renin-angiotensin-aldosterone system inhibitors. We report an analysis of French data from the PROKALE retrospective study, which assessed the management of recurrent hyperkalaemia in five European countries.

Mots clés

Cardiorenal syndrome, Chronic kidney disease, Heart failure, Hyperkalaemia, Hyperkaliémie, Inhibiteur du système Rénine-angiotensine-aldostérone, Insuffisance cardiaque, Insuffisance rénale chronique, Prognosis, Pronostic, Renin-angiotensin-aldosterone system inhibitors, Syndrome cardio-rénal

Référence

Nephrol Ther. 2021 May 11;: